Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.

Conclusions.
PMID: 29636358 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 10, 2018 Category: Cancer & Oncology Authors: McCoach CE, Le A, Gowan K, Jones KL, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC Tags: Clin Cancer Res Source Type: research